Recent advances and impending challenges for the radiopharmaceutical sciences in oncology

Lancet Oncol. 2024 Jun;25(6):e236-e249. doi: 10.1016/S1470-2045(24)00030-5.

Abstract

This paper is the first of a Series on theranostics that summarises the current landscape of the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we describe exciting developments in radiochemistry and the production of radionuclides, the development and translation of theranostics, and the application of artificial intelligence to our field. These developments are catalysing growth in the use of radiopharmaceuticals to the benefit of patients worldwide. We also highlight some of the key issues to be addressed in the coming years to realise the full potential of radiopharmaceuticals to treat cancer.

Publication types

  • Review

MeSH terms

  • Artificial Intelligence
  • Humans
  • Medical Oncology
  • Neoplasms* / radiotherapy
  • Neoplasms* / therapy
  • Radiopharmaceuticals* / therapeutic use

Substances

  • Radiopharmaceuticals